Why immunomodulatory therapies have not worked in sepsis

Intensive Care Medicine

Volumn 25, Issue 6, 1999, Pages 556-566

  Abraham, E ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HYBRID PROTEIN; IBUPROFEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCLONAL ANTIBODY; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR;

HUMAN; IMMUNOMODULATION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEPSIS; TREATMENT FAILURE;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS; ENDOTOXINS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, INTERLEUKIN-1; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; RESEARCH DESIGN; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032998431     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340050903     Document Type: Review

References (108)

1. 1. Abraham E (1997) Therapies for sepsis. Emerging therapies for sepsis and septic shock. West J Med 166: 195-200
2. 2. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP (1990) Septic shock in humans. Ann Intern Med 113: 227-242
3. 3. Zeni F, Freeman B, Natanson C (1997) Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med 25: 1095-1100
4. 4. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337: 1029-1035
5. 5. Lorenz HM, Antoni C, Valerius T, Repp R, Grunke M, Schwedtner N, Nusslein H, Woody J, Kalden JR, Manger B (1996) In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J Immunol 156: 1646-1653
6. 6. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN (1994) Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 344: 1125-1127
7. 7. Bone RC, Balk RA, Cerra FB et al. (1992) ACCP/SCCM consensus conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 101: 1644-1655
8. 8. Bone RC, Fisher CJ Jr, Clemmer TP et al. (1989) Sepsis syndrome: a valid clinical entity. Crit Care Med 17: 389-393
9. 9. Abraham E, Wunderink R, Silverman H et al. (1995) Monoclonal antibody to human tumor necrosis factor alpha (TNF MAb): efficacy and safety in patients with the sepsis syndrome. JAMA 273: 934-941
10. 10. Cohen J, Carlet J (1996) INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-α in patients with sepsis. Crit Care Med 24: 1431-1440
11. 11. Abraham E, Glauser MP, Butler T et al. (1997) p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. JAMA 277: 1531-1534
12. 12. Opal SM, Fisher CJ, Pribble JP, Dhainaut J-F, Vincent J-L, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, LaBreeque JF, Lookabaugh J, Donovan H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M the Interleukin-1 Receptor Antagonist Sepsis Investigator Group (1997) The confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 25: 1115-1124
13. 13. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S, for the NORASEPT H Study Group (1998) Monoclonal antibody to human tumor necrosis factor alpha (TNF Mab) in the treatment of patients with septic shock: a multi-center, placebo controlled, randomized, double-blind clinical trial. Lancet 351: 929-933
14. 14. Zanetti G, Heumann D, Gerain J et al. (1992) Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. J Immunol 148: 1890-1897
15. 15. Fisher CJ Jr, Agosti JM, Opal SM et al. (1996) Treatment of septic shock with the tumor necrosis factor receptor Fc fusion protein. N Engl J Med 334: 1697-1702
16. 16. Sprung CL, Finch RG, Thijs LG, Glauser MP (1996) International sepsis trial (INTERSEPT): role and impact of a clinical evaluation committee. Crit Care Med 24: 1441-1447
17. 17. Mollnes TE, Redl H, Hogasen K, Bengtsson A, Garred P, Speilberg L, Lea T, Oppermann M, Gotze O, Schlag G (1993) Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/ C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin Exp Immunol 91: 205-300
18. 18. Granowitz EV, Porat R, Gelfand JA, Wolff SM, Dinarello CA (1994) Administration of low-dose endotoxin to healthy humans increases C5a binding to circulating neutrophils. J Infect Dis 169: 480-482
19. 19. Coughlan AF, Hau H, Dunlop LC, Berndt MC, Hancock WW (1994) P-selectin and platelet-activating factor mediate initial endotoxin-induced netropenia. J Exp Med 179: 329-334
20. 20. Dhainaut JF, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet JP, Wolff M, Holzapfel L, Zeni F, Dreyfuss D, Mira JP et al. (1994) Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 22: 1720-1728
21. 21. Koltai M, Hosford D, Braquet PG (1993) Platelet-activating factor in septic shock. New Horiz 1: 87-95
22. 22. Kruse-Elliott KT, Albert DH, Summers JB, Carter GW, Zimmerman JJ, Grossman JE (1996) Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist. Shock 5: 265-273
23. 23. Ishii S, Nagase T, Tashiro F, Ikuta K, Sato S, Waga I, Kume K, Miyazaki J, Shimizu T (1997) Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. EMBO J 16: 133-142
24. 24. Coran AG, Drongowski RA, Paik JJ, Remick DG (1992) Ibuprofen intervention in canine septic shock: reduction of pathophysiology without decreased cytokines. J Surg Res 53: 272-279
25. 25. Mansilla-Rosello A, Ferron-Orihuela JA, Ruiz-Cabello F, Garrote-Lara D, Fernandez-Mondejar E, Delgado-Carvasco ML (1997) Differential effects of IL-1β and ibuprofen after endotoxic challenge in mice. J Surg Res 67: 199-204
26. 26. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA (1988) Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 81: 1162-1172
27. 27. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC et al. (1987) Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature 330: 662-664
28. 28. Fong Y, Tracey KJ, Moldawer LL et al. (1989) Antibodies to cachectin/TNF reduce interleukin-1 and interleukin-6 appearance during lethal bacteremia. J Exp Med 170: 1627-1633
29. 100 septic shock following therapy with antibody to tumor necrosis factor (TNF). Circ Shock 30: 279-292
30. 30. Van Zee KJ, Moldawer LL, Oldenburg HAS, Thompson WZ, Stackpole SA, Montegut WJ, Rogy MA, Meschter C, Gallati H. Schiller CD et al. (1996) Protection against lethal Escherichia coli bacteremia in baboons (Papio anubis) by pretreatment with a 55-kDa TNF receptor (CD120a)-Ig fusion protein, Ro 45-2081. J Immunol 156: 2221-2230
31. 31.Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 348: 550-552
32. 32. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA (1991) A specific receptor antagonist for interleukin-1 prevents Escherichia coli-induced shock. FASEB J 5: 338-343
33. 33. Chapman PB, Lester TJ, Casper ES et al. (1987) Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J Clin Oncol 5: 1942-1951
34. 34. Smith JW, Urba WJ, Curti BD et al. (1992) The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J Clin Oncol 10: 1141-1152
35. 35. Van der Poll T, Buller HR, ten Cate HT (1990) Activation of coagulation after administration of TNF to normal subjects. N Engl J Med 322: 1622-1627
36. 36. Endo S, Inada K, Nakae H et al. (1995) Plasma levels of type II phospholipase A2 and cytokines in patients with sepsis. Res Comm Mol Path Pharmacol 90:413-421
37. 37. Diaz A, Chepenik KP, Korn JH, Reginald AM, Jimenez SA (1998) Differential regulation of cyclooxygenases 1 and 2 by interleukin-1β, tumor necrosis factor-α, and transforming growth factor-β1 in human lung fibroblasts. Exp Cell Res 241: 222-229
38. 38. Newton R, Stevens DA, Hart LA, Lindsay M, Adcock IM, Barnes PJ (1997) Superinduction of COX-2 mRNA by cycloheximide and interleukin-1β involves increased transcription and correlates with increased NF-xB and JNK activation. FEBS Lett 418: 135-138
39. 39. Guan Z, Baier LD, Morrison AR (1997) p38 mitogen-activated protein kinnse down-regulates nitric oxide and up-regulates prostaglandin E2 biosynthesis stimulated by interleukin-1β. J Biol Chem 272: 8083-8089
40. 40. Moncada S, Palmer RMJ, Higgs EA (1991) Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-142
41. 41. Dinarello CA (1996) Biological basis for interleukin-1 in disease. Blood 87: 2095-2147
42. 42. Heremans H, van Damme J, Dillen C, Dikman R, Billiau A (1990) Interferon-γ, a mediator of lethal lipopolysaccharide-induced Shwartzman-like shock in mice. J Exp Med 171: 1853-1861
43. 43. Huang S. Hendriks W, Althage A et al. (1993) Immune response in mice that lack the interferon-gamma receptor. Science 259: 1742-1745
44. 44. Car BD, Eng VM, Schnyder B, Ozmen L, Huang S, Gallay P, Heumann D, Aguet M, Ryffel B (1994) Interferon gamma receptor deficient mice are resistant to endotoxic shock. J Exp Med 179: 1437-1444
45. 45. Herada A, Mukaida N, Matsushima K (1996) Interleukin-8 as a novel target for intervention therapy in acute inflammatory diseases. Mol Med Today 2: 482-489
46. 46. Zisman DA, Kunkel SL, Strieter RM, Gauldie J, Tsai WC, Bramson J, Wilkowski JM, Bucknell KA, Standiford TJ (1997) Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis. Shock 8: 349-356
47. 47. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, Cerami A, Bucala R (1995) MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377: 68-71
48. 48. Standiford TJ, Strieter RM, Lukacs NW, Kunkel SL (1995) Neutralization of IL-10 increases lethality in endotoxemia. J Immunol 155: 2222-2229
49. 49. Howard M, Muchamuel T, Andrade S, Menon S (1993) Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 177: 1205-1208
50. 50. Gerard C, Bruyns C, Marchant A, Abramowicz D, Vandenabeele P, Delvaux A, Fiers W, Goldman M, Velu T (1993) Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 177: 547-550
51. 51. Xu H, Gonzalo JA, St Pierre Y, Williams IR, Kupper TS, Cotran RS, Springer TA, Gutierrez-Ramos JC (1994) Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J Exp Med 180: 95-109
52. 52. Sessler CN, Windsor AC, Schwartz M, Watson L, Fisher BJ, Sugerman HJ, Fowler AA (1995) Circulating ICAM-1 is increased in septic shock. Am J Respir Crit Care Med 151: 1420-1427
53. 53. Watanabe S, Mukaida N, Ikeda N, Akiyama M, Harada A, Nakanishi I, Nariuchi H, Watanabe Y, Matsushima K (1995) Prevention of endotoxin shock by an antibody against leukocyte integrin beta 2 through inhibiting production and action of TNF. Int Immunol 7: 1037-1046
54. 54. Kayal S, Jais JP, Aguini N, Chaudiere J, Labrousse J (1998) Elevated circulating E-selectin, intracellular adhesion molecule 1, and von Willebrand factor in patients with severe infection. Am J Respir Crit Care Med 157: 776-784
55. 55. Hinshaw LB, Beller BK, Chang AC, Passey RB, Lahti RA, Flournoy DJ, Lane MM, Archer LT (1986) Effects of prior administration of steroids upon recovery from lethal sepsis. J Am Coll Surg 163: 335-344
56. 56. Hinshaw LB, Beller BK, Chang AC, Murray CK, Flournoy DJ, Passey RB, Archer LT (1985) Corticosteroid/antibiotic treatment of adrenalectomized dogs challenged with lethal E. coli. Circ Shock 16: 265-277
57. 57. Greisman SE, DuBuy JB, Woodward CL (1979) Experimental gram-negative bacterial sepsis: prevention of mortality not preventable by antibiotics alone. Infect Immunol 25: 538-557
58. 58. Schumer W (1976) Steroids in the treatment of clinical septic shock. Ann Surg 184: 333-341
59. 59. Cronin L, Cook DJ, Carlet J, Heyland DK, King D, Lansang MA, Fisher CJ (1995) Corticosteroid treatment for sepsis: a critical appraisal and metaanalysis of the literature. Crit Care Med 23: 1430-1439
60. 60. Lefering R, Neugebauer EA (1995) Steroid controversy in sepsis und septic shock: a meta analysis. Crit Care Med 23: 1294-1303
61. 61. Bernard GR, Luce JM, Sprung CL et al. (1987) High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 317: 1565-1570
62. 62. Bollaert PE, Charpentier C, Levy B, Debouverie M, Aduibert G, Larcan A (1998) Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 26: 645-650
63. 63. Doccke W-D, Randow F, Syrbe U, Krausch D, Asadullah K, Reincke P, Volk H-D, Kox W (1997) Monocyte deactivation in septic patients: restitution by IFNγ treatment. Nature Med 3: 678-681
64. 64. Kox WJ, Bone RC, Krausch D, Docke WD, Kox SN, Wauer H, Egerer K, Querner S, Asadullah K, von Baehr R, Volk HD (1997) Interferon γ-I b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle. Arch Intern Med 157: 389-393
65. 65. Nydegger UE (1997) Sepsis and poly-specific intravenous immunoglobulins. J Clin Apheresis 12: 93-99
66. 66. Werdan K, Pilz G (1996) Supplemental immune globulins in sepsis: a critical appraisal. Clin Exp Immunol 104 (Suppl 1): 83-90
67. 67. Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Brande AI (1982) Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 307: 1225-1230
68. 68. Zanetti G, Glauser MP, Baumgartner J (1991) Use of immunoglobulins in prevention and treatment of infection in critically ill patients: review and critique. Rev Infect Dis 13: 971-972
69. 69. Calandra T, Glauser MP, Schellekens J, Verhoef J (1988) Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J Infect Dis 158: 312-319
70. 70. J5 Study group (1992) Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J Infect Dis 165: 695-701
71. 71.The HA-1A Sepsis Study Group (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind placebo-controlled trial. N Engl J Med 324: 429-436
72. 72. Bone RC, Balk RA, Fein AM, Perl TM, Wenzel RP, Reines HD, Quenzer RW, Iberti TJ, MacIntyre N, Schein RM (1995) A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 23: 994-1006
73. 73. Greenman RL, Schein RM, Martin MA et al. (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. JAMA 266: 1097-1102
74. 74. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR (1994) Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121: 1-5
75. 75. Warren HS, Amato SF, Fitting C, Black KM, Loiselle PM, Pasternack MS, Cavaillon JM (1993) Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J Exp Med 177: 89-97
76. 76. Giroir BP, Quint PA, Barton P, Kirsch EA, Kitchen L, Goldstein B, Nelson BJ, Wedel NJ, Carroll SF, Scannon PJ (1997) Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsis. Lancet 350: 1439-1443
77. 23) decreases Escherichia coli-induced mortality and organ injury during immunosuppression-related neutropenia. Shock 4: 298-306
78. 78. Jin H, Yang R, Marsters S, Ashkenazi A, Bunting S, Marra MN, Scott RW, Baker JB (1995) Protection against endotoxic shock by bactericidal/permeability-increasing protein in rats. J Clin Invest 95: 1947-1952
79. 79. Heumann D, Lengacher S, Le Roy D, Jongeneel CV, Glauser MP (1998) The pathogenic role of LBP in gram-negative sepsis and septic shock. Prog Clin Biol Res 397: 379-386
80. 80. Lamping N, Dettmer R, Schroder NW, Pfeil D, Hallatschek W, Burger R, Schumann RR (1998) LPS-hinding protein protects mice from septic shock caused by LPS or gram-negative bacteria. J Clin Invest 101: 2065-2071
81. 81. Hawes AS, Fischer E, Marano MA, Van Zee KJ, Rock CS, Lowry SF, Calvano SE, Moldawer LL (1993) Comparison of peripheral blood leukocyte kinetics after live Excherichia coli, endotoxin, or interleukin-1 alpha administration. Studies using a novel interleukin-1 receptor antagonist. Ann Surg 218: 79-90
82. 82. Fischer E, Marano MA, Van Zee KJ, Rock CS, Hawes AS, Thompson WA, DeForge L, Kenney JS, Remick DG, Bloedow DC et al. (1992) Interleukin-1 receptor blockade improves survival and hemodynamic performance in Eschirichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89: 1551-1557
83. 83. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedow DC, Catalano MA (1994) Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit Care Med 22: 12-21
84. 84. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL et al. (1994) Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271: 1836-1843
85. 85. Hinshaw LB, Emerson TE Jr, Taylor FB Jr, Chang ACK, Duerr M, Peer GT, Flournoy DJ, White GL, Kosanake SD, Murray CK, Xu R, Passey RB, Fournel MA (1992) Lethal S. aureus shock in primates: prevention of death with anti-TNF antibody. J Trauma 33: 568-573
86. 86. Vincent JL, Bakker J, Marccaux G, Schandene L, Kahn RJ, Dupont E (1992) Administration of inti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study. Chest 101: 810-815
87. 87. Dhainaut J-F A, Vincent J-L, Richard C, Lejeune P, Martin C, Fierobe L, Stephens S, Ney UM, Sopwith M (1995) CDP571, a humanized antibody to human tumor necrosis factor-α: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. Crit Care Med 23: 1461-1469
88. 88. Reinhart K, Wiegand-Lohnert C, Grimminger F et al. (1996) Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 24: 733-742
89. 89. Fisher CJ Jr, Agosti JM, Opal SM et al. (1996) Treatment of septic shock with the tumor necrosis factor receptor Fc fusion protein. N Engl J Med 334: 1697-1702
90. 90. Abraham E (1998) Presented at the American Thoracic Society International Conference, April 28, 1998
91. 91. Fekade D, Knox K, Hussein K, Melka A, Lalloo DG, Coxon RE, Warrell DA (1996) Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med 335: 311-315
92. 92. Bone RC (1994) Gram-positive organisms and sepsis. Arch Intern Med 154: 26-34
93. 93. Bone RC, Fisher CJ, Clemmer TP, et al (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 653-658
94. 94. Luce JM, Montgomery AB, Marks JA, et al (1988) Ineffectiveness of high dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am Rev Respir Dis 138: 62-68
95. 95. The Veterans Administration Systemic Sepsis Cooperative Study Group (1987) Effect of high-dose glucocorticosteroid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 317: 659-665
96. 96. Sprung CL, Caralis PV, Marcial EH, et al (1984) The effect of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 311: 1137-1143
97. 97. Cooperative Study Group (1963) The effectiveness of hydrocortisone in the management of severe infections. JAMA 183: 462-465
98. 98. Lucas C, Ledgerwood A (1984) The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch Surg 119: 537-541
99. 99. Klastersky J, Cappel R, Debusscher L (1971) Effectiveness of betamethasone in management of severe infections. N Engl J Med 284: 1248-1250
100. 100. Thompson WL, Gurley H, Lutz B, et al (1976) Inefficacy of corticosteroids in shock. Clin Res 24: 258 A
101. 101. Opal SM, Fisher CJ, Pribble JP, Dhainaut J-F, Vincent J-L, Brase R, Lowry SF, Sadoff JC, Slotman GJ, Levy H, Balk RA, Shelly MP, LaBrecque JF, Lookahaugh J, Donovan H, Baughman R, Norman J, DeMaria E, Matzel K, Abrahama E, Seneff M, and the Interleukin-1 Receptor Antagonist Sepsis Investigator Group (1997) The confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III randomized, double-blind, placebo-controlled, multicenter trial. Crit Care Med 25: 1115-1124
102. 102. Fein AM, Bernard GR, Criner GJ, et al (1997) Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, Deltibant (CP-0127). JAMA 277: 482-487
103. 103. Natanson C, Esposito CJ, Banks SM (1998) The sirens' songs of confirmatory sepsis trials: selection bias and sampling error. Crit Care Med 26: 1927-1931
104. 104. Dhainaut JF, Tenaillon A, Le Tulzo Y, et al (1994) Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomised double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 22: 1720-1728
105. 105. Dhainaut JF, Tenaillon A, Hemmer M, et al (1998) Confirmatory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: a phase III, randomized double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 26: 1963-1971
106. 106. Bernard GR, Reines HD, Halushka PV (1991) Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome: effects of cyclooxygenase inhibition. Am Rev Respir Dis 144: 1095-1101
107. 107. Bernard GR, Wheeler AP, Russel JA, et al (1997) The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 336: 912-918
108. 108. Kopf M, Baumann H, Freer G, et al (1994) Impaired immune and acute phase responses in interleukin-6-deficient mice. Nature 368: 339-342